Article date: November 1996
By: J. DRAKE, C.E. HORTH &, F.E. CRAWFORD, in Volume 42, Issue 5, pages 646-647
Oramorph SR (OSR) meets design specification criteria similar to those of MST Continus (MST); both are modified‐release tablets with similar in vitro dissolution rates. Our study [1] like that sponsored by Napp Laboratories (Houston & Yeang [2]) compared these two, essentially similar formulations in healthy subjects under fasting and fed conditions. In dispute is the interpretation of what are probably two similar data sets. Houston & Yeang made conclusions about the quality and reliability of OSR based selectively on the Cmax data. Their analysis made no direct statistical comparison between the two formulations and no plasma morphine vs time profile was published. Our study was carried out to provide data for what we consider to be a more in‐depth analysis.
DOI: 10.1111/j.1365-2125.1996.tb00125.x
View this article